PortalPublikationenPatterns of TIGIT Expression in Lymphatic Tissue, Inflammati...

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer

Standard

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. / Blessin, Niclas C; Simon, Ronald; Kluth, Martina; Fischer, Kristine; Hube-Magg, Claudia; Li, Wenchao; Makrypidi-Fraune, Georgia; Wellge, Björn; Mandelkow, Tim; Debatin, Nicolaus F; Höflmayer, Doris; Lennartz, Maximilian; Sauter, Guido; Izbicki, Jakob R; Minner, Sarah; Büscheck, Franziska; Uhlig, Ria; Dum, David; Krech, Till; Luebke, Andreas M; Wittmer, Corinna; Jacobsen, Frank; Burandt, Eike-Christian; Steurer, Stefan; Wilczak, Waldemar; Hinsch, Andrea.

in: DIS MARKERS, Jahrgang 2019, 2019, S. 5160565.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Blessin, NC, Simon, R, Kluth, M, Fischer, K, Hube-Magg, C, Li, W, Makrypidi-Fraune, G, Wellge, B, Mandelkow, T, Debatin, NF, Höflmayer, D, Lennartz, M, Sauter, G, Izbicki, JR, Minner, S, Büscheck, F, Uhlig, R, Dum, D, Krech, T, Luebke, AM, Wittmer, C, Jacobsen, F, Burandt, E-C, Steurer, S, Wilczak, W & Hinsch, A 2019, 'Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer', DIS MARKERS, Jg. 2019, S. 5160565. https://doi.org/10.1155/2019/5160565

APA

Blessin, N. C., Simon, R., Kluth, M., Fischer, K., Hube-Magg, C., Li, W., Makrypidi-Fraune, G., Wellge, B., Mandelkow, T., Debatin, N. F., Höflmayer, D., Lennartz, M., Sauter, G., Izbicki, J. R., Minner, S., Büscheck, F., Uhlig, R., Dum, D., Krech, T., ... Hinsch, A. (2019). Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. DIS MARKERS, 2019, 5160565. https://doi.org/10.1155/2019/5160565

Vancouver

Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W et al. Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. DIS MARKERS. 2019;2019:5160565. https://doi.org/10.1155/2019/5160565

Bibtex

@article{c10bc1e644ca41f5b35bd68833188165,
title = "Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer",
abstract = "TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and various inflamed tissues, colorectal and lung cancers, as well as >1700 tumour samples from 86 different tumour entities for TIGIT and/or PD-1 by bright field and/or multiplex fluorescence immunohistochemistry. TIGIT was detected in CD8+ cytotoxic T cells, CD4+ T helper cells, FOXP3+ regulatory T cells, and NK cells, but not in CD11c+ dendritic cells, CD68+ macrophages, and CD20+ B lymphocytes. TIGIT expression paralleled that of PD-1. More than 70% of TIGIT+ cells were PD-1+, and more than 90% of the PD-1+ cells were TIGIT+. Expression varied between different tissue compartments. TIGIT expression in tonsil gradually increased from the interfollicular area over the marginal/mantle zone to the germinal centre in all T cell subtypes. In inflammatory diseases, the strongest expression of TIGIT/PD-1 was found in Hashimoto thyroiditis. TIGIT+ lymphocytes were seen in all 86 different tumour entities with considerable high variability of TIGIT positivity within and between different cancer entities. Particularly, high densities of TIGIT+ lymphocytes were, for example, seen in squamous cell cancers of various origins. In summary, the variable expression levels of TIGIT and PD-1 in cell types and tissue compartments illustrate the high complexity of immune microenvironments. The high frequency of TIGIT (and PD-1) expressing lymphocytes in cancers highlights considerable opportunities for cotargeting with checkpoint inhibitors.",
keywords = "Humans, Immune System Diseases/genetics, Lymph Nodes/metabolism, Neoplasms/genetics, Palatine Tonsil/metabolism, Receptors, Immunologic/genetics",
author = "Blessin, {Niclas C} and Ronald Simon and Martina Kluth and Kristine Fischer and Claudia Hube-Magg and Wenchao Li and Georgia Makrypidi-Fraune and Bj{\"o}rn Wellge and Tim Mandelkow and Debatin, {Nicolaus F} and Doris H{\"o}flmayer and Maximilian Lennartz and Guido Sauter and Izbicki, {Jakob R} and Sarah Minner and Franziska B{\"u}scheck and Ria Uhlig and David Dum and Till Krech and Luebke, {Andreas M} and Corinna Wittmer and Frank Jacobsen and Eike-Christian Burandt and Stefan Steurer and Waldemar Wilczak and Andrea Hinsch",
year = "2019",
doi = "10.1155/2019/5160565",
language = "English",
volume = "2019",
pages = "5160565",
journal = "DIS MARKERS",
issn = "0278-0240",
publisher = "IOS Press",

}

RIS

TY - JOUR

T1 - Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer

AU - Blessin, Niclas C

AU - Simon, Ronald

AU - Kluth, Martina

AU - Fischer, Kristine

AU - Hube-Magg, Claudia

AU - Li, Wenchao

AU - Makrypidi-Fraune, Georgia

AU - Wellge, Björn

AU - Mandelkow, Tim

AU - Debatin, Nicolaus F

AU - Höflmayer, Doris

AU - Lennartz, Maximilian

AU - Sauter, Guido

AU - Izbicki, Jakob R

AU - Minner, Sarah

AU - Büscheck, Franziska

AU - Uhlig, Ria

AU - Dum, David

AU - Krech, Till

AU - Luebke, Andreas M

AU - Wittmer, Corinna

AU - Jacobsen, Frank

AU - Burandt, Eike-Christian

AU - Steurer, Stefan

AU - Wilczak, Waldemar

AU - Hinsch, Andrea

PY - 2019

Y1 - 2019

N2 - TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and various inflamed tissues, colorectal and lung cancers, as well as >1700 tumour samples from 86 different tumour entities for TIGIT and/or PD-1 by bright field and/or multiplex fluorescence immunohistochemistry. TIGIT was detected in CD8+ cytotoxic T cells, CD4+ T helper cells, FOXP3+ regulatory T cells, and NK cells, but not in CD11c+ dendritic cells, CD68+ macrophages, and CD20+ B lymphocytes. TIGIT expression paralleled that of PD-1. More than 70% of TIGIT+ cells were PD-1+, and more than 90% of the PD-1+ cells were TIGIT+. Expression varied between different tissue compartments. TIGIT expression in tonsil gradually increased from the interfollicular area over the marginal/mantle zone to the germinal centre in all T cell subtypes. In inflammatory diseases, the strongest expression of TIGIT/PD-1 was found in Hashimoto thyroiditis. TIGIT+ lymphocytes were seen in all 86 different tumour entities with considerable high variability of TIGIT positivity within and between different cancer entities. Particularly, high densities of TIGIT+ lymphocytes were, for example, seen in squamous cell cancers of various origins. In summary, the variable expression levels of TIGIT and PD-1 in cell types and tissue compartments illustrate the high complexity of immune microenvironments. The high frequency of TIGIT (and PD-1) expressing lymphocytes in cancers highlights considerable opportunities for cotargeting with checkpoint inhibitors.

AB - TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and various inflamed tissues, colorectal and lung cancers, as well as >1700 tumour samples from 86 different tumour entities for TIGIT and/or PD-1 by bright field and/or multiplex fluorescence immunohistochemistry. TIGIT was detected in CD8+ cytotoxic T cells, CD4+ T helper cells, FOXP3+ regulatory T cells, and NK cells, but not in CD11c+ dendritic cells, CD68+ macrophages, and CD20+ B lymphocytes. TIGIT expression paralleled that of PD-1. More than 70% of TIGIT+ cells were PD-1+, and more than 90% of the PD-1+ cells were TIGIT+. Expression varied between different tissue compartments. TIGIT expression in tonsil gradually increased from the interfollicular area over the marginal/mantle zone to the germinal centre in all T cell subtypes. In inflammatory diseases, the strongest expression of TIGIT/PD-1 was found in Hashimoto thyroiditis. TIGIT+ lymphocytes were seen in all 86 different tumour entities with considerable high variability of TIGIT positivity within and between different cancer entities. Particularly, high densities of TIGIT+ lymphocytes were, for example, seen in squamous cell cancers of various origins. In summary, the variable expression levels of TIGIT and PD-1 in cell types and tissue compartments illustrate the high complexity of immune microenvironments. The high frequency of TIGIT (and PD-1) expressing lymphocytes in cancers highlights considerable opportunities for cotargeting with checkpoint inhibitors.

KW - Humans

KW - Immune System Diseases/genetics

KW - Lymph Nodes/metabolism

KW - Neoplasms/genetics

KW - Palatine Tonsil/metabolism

KW - Receptors, Immunologic/genetics

U2 - 10.1155/2019/5160565

DO - 10.1155/2019/5160565

M3 - SCORING: Journal article

C2 - 30733837

VL - 2019

SP - 5160565

JO - DIS MARKERS

JF - DIS MARKERS

SN - 0278-0240

ER -